Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]
Candel Therapeutics, Inc. (CADL)
Company Research
Source: Yahoo! Finance
Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3 trials and a planned regulatory filing while reporting its fourth quarter and full-year 2025 financial results. “During the quarter, we made meaningful progress across our clinical pipeline and pre-commercial readiness, entering 2026 with strong momentum and a robust set of potential value-driving catalysts,” Candel CEO Paul Peter Tak said in a statement. The clinical-stage biopharmaceutical company said it plans to initiate a pivotal phase 3 clinical trial of its lead candidate, aglatimagene besadenovec (CAN-2409), in patients with progressive metastatic non-squamous non-small cell lung cancer (NSCLC) who have failed immune checkpoint inhibitor treatment in the second quarter of 2026. The company also intends to submit a Biologics License Application (BLA) for the therapy in localized intermediate- to high-risk prostate cancer
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.MarketBeat
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting [Yahoo! Finance]Yahoo! Finance
CADL
Earnings
- 3/12/26 - Miss
CADL
Sec Filings
- 3/12/26 - Form S-8
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- CADL's page on the SEC website